Stuttering. Childhood onset fluency disorder
Conditions
Interventions
Intervention 1: Intervention group:Intervention group: Patients in the drug group were treated with risperidone with a nightly unit dose of half a milligram and a maximum nightly unit dose of up to tw
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 10 Years
Inclusion criteria
Inclusion criteria: 1. Age range from 5 to 10 years 2. Having a diagnosis of developmental stuttering disorder based on the score of the SSI-3 test and the therapist's speech diagnosis 3. Absence of any language, speech or reading disorders other than stuttering 4. Absence of any kind of neurological, movement, vision, hearing, mental-cognitive problems in the past or present 5. Not taking drugs affecting cognitive function or stuttering, in the last month or during research 6. Absence of history of speech therapy treatment at least in the last 3 months
Exclusion criteria
Exclusion criteria: The individual's unwillingness to cooperate in any stage of the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of stuttering severity using the SSI-3 measurement tool by an evaluator (experienced speech therapist) and the SR score by the individual at the beginning of the study, 4 weeks and 10 weeks after the start of treatment during a visit to the clinic. Timepoint: Zero, 4 and 10 weeks. Method of measurement: SSI-3 SR self-report form, AIMS, Connors hyperactivity test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigating the severity of stuttering using the SSI-3 measurement tool and the SR score. Timepoint: zero, four and ten weeks after the start of treatment. Method of measurement: Stuttering Severity Instrument-3.;Investigating the duration of recovery of stuttering based on SR and SSI-3 scores. Timepoint: zero, four and ten weeks after the start of treatment. Method of measurement: Self-Report Self-Report Form - Connors Hyperactivity.;Investigating age and gender differences in the group receiving risperidone. Timepoint: zero, four and ten weeks after the start of treatment. Method of measurement: Abnormal Involuntary Movement Scale (AIMS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Arman Masoodi
Babol University of Medical Sciences
Outcome results
None listed